Baxfendy (baxdrostat): FDA approval, pivotal trial and safety
Approved
Type
New molecular entity · Oral
FDA-approved use
To treat hypertension in combination with other antihypertensive drugsWording from FDA's list of novel approvals.
FDA review
Priority review
Company
AstraZeneca
Application
NDA 219878
Specialty
Cardiology
At a glance
Baxfendy is the first aldosterone synthase inhibitor, approved as an add-on for adults whose blood pressure stays above goal on other drugs. In the phase 3 BaxHTN trial it lowered seated systolic pressure by about 9 to 10 mm Hg more than placebo at 12 weeks, and in Bax24 it lowered 24-hour ambulatory systolic pressure by 14 mm Hg more than placebo. Hyperkalemia is the main risk to watch.
What it is and how it works
Aldosterone excess drives a large share of hard-to-control hypertension through sodium and water retention and vascular stiffening. Baxdrostat inhibits aldosterone synthase, the enzyme that makes aldosterone, and is selective enough to spare 11-beta-hydroxylase, so cortisol production is not suppressed. Mineralocorticoid receptor antagonists such as spironolactone work one step later, by blocking aldosterone's receptor.
Phase 3, multinational, randomized (1:1:1), double-blind, placebo-controlled; two doses or placebo for 12 weeks after a 2-week placebo run-in, then open-label and randomized-withdrawal periods.
Patients
794 treated adults with seated systolic pressure 140 to under 170 mm Hg on two drugs (uncontrolled) or three or more (resistant), including a diuretic; mean baseline 149/87 mm Hg.
Compared with
Placebo, on top of background therapy.
Primary endpoint
Change in seated systolic blood pressure from baseline to week 12.
Result
Systolic pressure fell 14.5 and 15.7 mm Hg with the two doses versus 5.8 mm Hg with placebo: placebo-corrected differences of -8.7 mm Hg (95% CI, -11.5 to -5.8) and -9.8 mm Hg (95% CI, -12.6 to -7.0); P<0.001 for both.
Safety in the trial
Potassium above 6.0 mmol/L in 2.3% and 3.0% versus 0.4% with placebo.
How does Baxfendy (baxdrostat) compare with the alternatives (Spironolactone, Eplerenone, Aprocitentan) for hypertension in combination with other antihypertensive drugs? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseOpens in a new tab. Nothing is sent until you press Ask. Free to try, more with 2MM+.
Deep research is a core feature of 2MM Max.
Safety signals
Potassium rose above 6.0 mmol/L in 2.3% to 3.0% of patients on baxdrostat in BaxHTN versus 0.4% on placebo, and in 3% versus none in Bax24. The label asks for potassium and sodium checks before starting and periodically after, more often in patients 65 or older and those with diabetes, chronic kidney disease or drugs that raise potassium. The trials did not allow mineralocorticoid receptor antagonists, potassium-sparing diuretics or an ACE inhibitor combined with an ARB, and required an eGFR of at least 45. There are no outcome trials yet: the label's statement on reducing strokes and heart attacks comes from blood pressure lowering in general.
What it competes with
Spironolactone is the usual fourth drug for resistant hypertension. Baxfendy has not been compared with it head to head; it offers a different way to lower aldosterone's effect without the sex-hormone side effects of spironolactone.
SpironolactoneUsual fourth-line drug for resistant hypertension; blocks the aldosterone receptor.
AprocitentanEndothelin receptor antagonist approved for resistant hypertension.
Renal denervationDevice-based option for uncontrolled hypertension.
Bottom line for clinicians
For uncontrolled or resistant hypertension despite two or more drugs including a diuretic, Baxfendy adds about 9 to 14 mm Hg of systolic lowering. Check potassium and sodium before and during treatment, be careful in CKD, and note that the trials excluded patients already on a mineralocorticoid receptor antagonist.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated October 27, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.
Get the app